A new weight-based secukinumab formulation provides a new option for treatment of adolescents with moderate-to-severe hidradenitis suppurativa (HS) with the FDA’s approval, according to a press ...

The FDA approved secukimumab for children aged 12 years and older with moderate to severe hidradenitis suppurativa, Novartis announced in a press release.The approval makes secukinumab (Cosentyx) the ...

Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval for those aged 12 and up.

The FDA has approved secukinumab (Cosentyx; Novartis) for the treatment of pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), the company announced. 1 The ...

In a recent trial, secukinumab -- a monoclonal anti-interleukin-17A antibody -- eased chronic itching in people with psoriasis. However, pruritus quickly recurred when secukinumab was switched to ...

Novartis received positive news when the U.S. Food and Drug Administration (:FDA) approved Xolair for an additional indication. Xolair is now approved in the U.S. for the treatment of chronic ...

Please provide your email address to receive an email when new articles are posted on . Secukinumab demonstrated rapid, stained improvements in fatigue for up to 3 years among patients with ankylosing ...

psoriasis The new findings come from an uncontrolled extension of two previous secukinumab trials in which patients were re-randomized to placebo following PASI achievement. Patients with moderate to ...

Patients with axial spondyloarthritis treated with secukinumab achieved a reduction in spinal pain and improved disease activity measures early in treatment. Secukinumab can effectively reduce spinal ...

In a phase II trial that enrolled 52 patients, 70.1% (95% CI 51.6-84.9) of those who were randomized to secukinumab were in sustained remission at week 28 compared with 20.3% (95% CI 12.4-30) of those ...

Secukinumab is a recombinant human monoclonal antibody which is used in the treatment of moderate-to-severe plaque psoriasis (a type of skin disease with red and scaly patches in parts of the body), ...

The monoclonal antibody secukinumab is approved for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of six years who are candidates for systemic therapy.